Navigation Links
VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions

actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that the EvaMist NDA submission will be approved in a timely basis, or at all. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10- K for the year ended December 31, 2006 and periodic reports filed with the Securities and Exchange Commission.

Contact

VIVUS, Inc.
Timothy E. Morris, 650-934-5200
Chief Financial Officer
or
The Trout Group
Ian Clements (SF), 415-392-3385
Brian Korb (NYC), 646-378-2923


'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:4/24/2015)... -- Bayer Corporation hosted its annual "Take Your Child to Work ... headquarters.  This is Bayer,s second "Take Your Child To Work ... campus, and Thursday,s event welcomed 230 children ready to see ... Fortunately, for the kids, this was not just another ... "Science For A Better Life," Bayer made sure that "Take ...
(Date:4/24/2015)... , April 24, 2015   Vestagen Technical ... technology, VESTEX ® , has recently received two notable ... a global competition that recognizes innovations with potential to ... ceremony last night in New York City ... the Material Science "Protection & Safety" category. The awards ...
(Date:4/24/2015)... Introduction of new ... tools for radiosurgery/SBRT   The "Elements" ... enhancing the workflow for difficult to treat indications ... - comes full circle with the introduction of ... Elements enable on-the-fly generation of consistent treatment plans ...
Breaking Medicine Technology:Bayer Hosts "Take Your Child to Work Day" 2Bayer Hosts "Take Your Child to Work Day" 3Bayer Hosts "Take Your Child to Work Day" 4VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2
... BOSTON, Dec. 9 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... sales for the month of October 2009 and $42,898.42 in ... October 2008 and $32,028.52 for November 2008 respectively. , About ... instrument company whose mission is to develop and market breakthrough ...
... , , , GAITHERSBURG, Md, ... in the development and manufacture of lentiviral gene delivery ... Institutes of Health (NIH) small business innovation research (SBIR) ... Generating Hepatitis C Virus-Like Particles using Lentivirus". In ...
Cached Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:4/27/2015)... 2015 Final Cut Pro X ... ProTelestrator from Pixel Film Studios. A telestrator is a device ... a moving or still video image. Telestrators are often used ... plays or incoming weather patterns. , After users are done ... the frame slider to control the speed of the animation. ...
(Date:4/27/2015)... PREVENT Life Safety, America’s premier provider of ... the addition of an account manager in Houston. In ... growing customer base, Curtis Rice, an experienced sales professional, ... Manager. Curtis has been added to the team to ... Houston area and beyond. , Curtis brings ...
(Date:4/27/2015)... 2015 Launched by a group ... offered consumers a way to connect to top ... Using a patent-pending Pick Your Price matching algorithm, ... Botox®, laser hair removal and dermal fillers on ... gaps in their schedules. This allows clients to ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 A ... 2015 in the U.S. District Court, Northern District ... ( http://www.testosteronelawsuithub.com/ ) have been consolidated for ... court documents, matters addressed included the intention of ... claims involving their products on preemption grounds, with ...
(Date:4/26/2015)... 26, 2015 Indiana Fiber Network, LLC ... that Brotherhood Mutual Insurance Company has selected IFN as ... Network Infrastructure at Brotherhood Mutual Insurance Company states: “IFN’s ... reliability Brotherhood Mutual needed. We were interested ... worked with us to ensure we achieved both. ” ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2Health News:PREVENT Life Safety Services Welcomes Curtis Rice as a New Senior Account Manager in Houston, TX 2Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 2Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 3Health News:Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference 4Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3
... ... on Allied Health Personnel in Ophthalmology (JCAHPO), and the Association of Technical Personnel in ... A Clinical Skills and Reference Guide for the Ophthalmic Technician. , ... St. Paul, MN (Vocus) November ...
... Asher, MD, FACS, of Carolina Neurosurgery & Spine Associates ... treatment guidelines for brain metastases patients. These guidelines were ... Annual Meeting in New Orleans, and were developed over ... medical specialties. Members of the panel analyzed 25,000 brain ...
... Nov. 10 Roxane Laboratories, Inc. announced today the ... Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the ... available in bottles of 100 for immediate shipment to ... Tablets are AB rated to ACEON® (perindopril erbumine) tablets. ...
... be questionable, expert says , TUESDAY, Nov. 10 (HealthDay ... reduce the incidence of gallstones and the need for ... new study indicates. , "We,re talking about people who ... Susan S. Jick, director of the Boston Collaborative Drug ...
... rate of nearly 1 in 4 people , TUESDAY, Nov. ... on Medicare who are hospitalized for heart failure are back ... study reveals. , That should not be happening, said Dr. ... medicine at the Mount Sinai School of Medicine in New ...
... tumours in 50% of mice in a new study published today ... drug also stopped lung cancer tumours from growing and becoming resistant ... are now planning to take the drug into clinical trials, to ... form of lung cancer. One in five people with lung ...
Cached Medicine News:Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 2Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 3Health News:Local Neurosurgeon Co-Authors National Treatment Guidelines for Brain Tumor Patients 2Health News:Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets 2Health News:Statins May Stave Off Gallstones 2Health News:Statins May Stave Off Gallstones 3Health News:The Revolving Door of Heart Failure Hospitalization 2Health News:The Revolving Door of Heart Failure Hospitalization 3Health News:Drug shrinks lung cancer tumors in mice 2Health News:Drug shrinks lung cancer tumors in mice 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 9.0 mm and length 7.5 mm....
Medicine Products: